Search clinical trials for: AS1411

Total 76 results

Antisoma Research

Unknown

A Phase II Study of AS1411 in Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
Antisoma Research

Completed

Study of AS1411 in Advanced Solid Tumours

Advanced Solid Tumors

United States
Antisoma Research

Completed

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Leukemia, Myeloid

United States, New Zealand
Ascendo Biotechnology Co., Ltd.

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

Metastatic Solid Tumor
Ascletis Pharmaceuticals Co., Ltd.
Hunan Provincial People's Hospital

Completed

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Healthy

China
Akeso

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer

ER Positive/HER2 Low Breast Cancer

China
Avigen

Completed

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

Diabetic Neuropathy

Australia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Gannex Pharma Co., Ltd.

Recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Gynaecological Malignancies

China
Akeso

Completed

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

Psoriasis

China
Akeso

Recruiting

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Atridia Pty Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumors

China, Korea, Republic of, Taiwan, United States, Australia
Akeso

Completed

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Akeso

Completed

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Psoriasis

China
Gannex Pharma Co., Ltd.
Hunan Provincial People's Hospital

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

Healthy | NAFLD | Hyperlipidemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Gastric Cancer | Colorectal Cancer

China
Akeso

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Gannex Pharma Co., Ltd.

Withdrawn

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Nonalcoholic Steatohepatitis (NASH)
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

HER2-expressing Advanced Solid Tumors

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Mayo Clinic

Enrolling by invitation

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders (AND1)

Parkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic Aphasia

United States
Akesobio Australia Pty Ltd

Completed

A Study of AK111 in Healthy Subjects

Psoriasis

New Zealand
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Lung Cancer

China
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

COVID-19 | Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Breast Cancer

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Antisoma Research

Terminated

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Taiwan, Australia, New Zealand
Johns Hopkins University
National Institute on Aging (NIA)

Withdrawn

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

Healthy | Alzheimer Disease

United States
Fudan University

Active, not recruiting

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Breast Cancer

China
Antisoma Research

Completed

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
Bristol-Myers Squibb

Withdrawn

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma (MDX1411-02)

Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Advanced Colorectal Cancer

China
Bristol-Myers Squibb

Completed

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. (MDX1411-01)

Kidney Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

HER2 Low Advanced or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer
Mayo Clinic

Enrolling by invitation

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

Brain Imaging | Whole Body Imaging

United States
Micelle BioPharma Inc

Unknown

Dose-Finding Study of SC411 in Children With Sickle Cell Disease (SCOT)

Sickle Cell Disease

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Cancer Research UK
Cancer Society Auckland

Completed

Study of DMXAA (Now Known as ASA404) in Solid Tumors (DMXAA)

Solid Tumors
Huihua Xiong

Not yet recruiting

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Breasr Cancer
Micelle BioPharma Inc

Unknown

A Sickle CEll Disease ComplicatioN Trial (ASCENT)

Sickle Cell Disease

3

Subscribe